08:00 , Jan 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lysine-specific demethylase 1 (LSD1; KDM1A)

Cancer INDICATION: Leukemia In vitro and mouse studies identified tranylcypromine-based inhibitors of LSD1 that could help treat leukemia. Chemical synthesis and in vitro testing of tranylcypromine analogs identified three compounds that inhibited LSD1 with IC50...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

4SC-202: Phase I data

Top-line data from the open-label, dose-escalation, German Phase I TOPAS trial in 24 patients with advanced hematological malignancies showed that 25-400 mg oral 4SC-202 for 14 days in 21-day cycles led to 1 complete remission...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Clinical News

4SC-202: Phase I started

4SC began the open-label, dose-escalation, German Phase I TOPAS trial to evaluate 25-400 mg oral 4SC-202 for 14 days in 21-day cycles in up to 36 patients. 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany   Product: 4SC-202...